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Background: Immunoassays that employ multiplexed bead arrays produce high information content per sample. Such
assays are now frequently used to evaluate humoral responses in clinical trials. Integrated software is needed for the
analysis, quality control, and secure sharing of the high volume of data produced by such multiplexed assays. Software
that facilitates data exchange and provides flexibility to perform customized analyses (including multiple curve fits and
visualizations of assay performance over time) could increase scientists’ capacity to use these immunoassays to evaluate
human clinical trials.
Results: The HIV Vaccine Trials Network and the Statistical Center for HIV/AIDS Research and Prevention collaborated with
LabKey Software to enhance the open source LabKey Server platform to facilitate workflows for multiplexed bead assays.
This system now supports the management, analysis, quality control, and secure sharing of data from multiplexed
immunoassays that leverage Luminex xMAP® technology. These assays may be custom or kit-based. Newly added features
enable labs to: (i) import run data from spreadsheets output by Bio-Plex Manager™ software; (ii) customize data processing,
curve fits, and algorithms through scripts written in common languages, such as R; (iii) select script-defined calculation
options through a graphical user interface; (iv) collect custom metadata for each titration, analyte, run and batch of runs; (v)
calculate dose–response curves for titrations; (vi) interpolate unknown concentrations from curves for titrated standards; (vii)
flag run data for exclusion from analysis; (viii) track quality control metrics across runs using Levey-Jennings plots; and (ix)
automatically flag outliers based on expected values. Existing system features allow researchers to analyze, integrate,
visualize, export and securely share their data, as well as to construct custom user interfaces and workflows.
Conclusions: Unlike other tools tailored for Luminex immunoassays, LabKey Server allows labs to customize their
Luminex analyses using scripting while still presenting users with a single, graphical interface for processing and analyzing
data. The LabKey Server system also stands out among Luminex tools for enabling smooth, secure transfer of data, quality
control information, and analyses between collaborators. LabKey Server and its Luminex features are freely available as
open source software at http://www.labkey.com under the Apache 2.0 license.Background
Multiplexed bead arrays allow researchers to perform im-
munoassays that test tens or even hundreds of analytes
against each sample in each plate well [1-18]. At present,
many [19-23] (but not all [24,25]) of these arrays leverage
Luminex® xMAP® technology, so we refer to them here as
“Luminex” assays. These include both commercially avail-
able assay kits and custom assays, such as the binding* Correspondence: eknelson@labkey.com
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reproduction in any medium, provided the orantibody multiplex assay (BAMA) for human immuno-
deficiency virus 1 (HIV-1) developed by the Tomaras La-
boratory at Duke University [5]. Such multiplexed assays
can speed experimental efforts, increase lab efficiency and
consume smaller amounts of sample material than ordin-
ary enzyme-linked immunosorbent assays (ELISAs)
[7,10,11,15,26]. In an ELISA, each analyte must be tested
with a separate aliquot of sample in a separate well. Al-
though Luminex assays can offer experimental advantages,
they can also pose challenges in analysis [27] and quality
control [15-17,28-30], particularly given the greatertd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ary ELISAs. The continued evolution of analysis and qual-
ity control techniques, the limits of current tools and the
increasingly important role these assays play in certain
fields of biomedical research all make enhanced software
tools desirable for management and analysis of Luminex
immunoassay data.
The field of vaccine immunology provides an example
of the growing importance of Luminex assays and the
need for better software support. In this field, samples
from vaccine trial participants can be too scarce to assay
against large numbers of analytes using ordinary ELISA
techniques [10,11]. To maximize the insights gained
from vaccine trials, researchers have started to rely on
multiplexed Luminex methods [1-3,9-14]. Recent follow-
up studies for the ALVAC-AIDSVAX trial, the first vac-
cine trial ever to demonstrate some degree of vaccine ef-
ficacy against HIV-1 [1,31], heavily used Luminex assays.
Several of these studies used Luminex assays to examine
the binding of plasma immunoglobulins to panels of
HIV-1 envelope proteins to determine immune corre-
lates of vaccine efficacy [1,5].
While completing ALVAC-AIDSVAX follow-up stud-
ies, several collaborating teams found that the existing
software for analysis and quality control of research
Luminex immunoassays did not meet their needs in two
areas. First, labs found it necessary to move data be-
tween multiple software tools to fully process all experi-
mental data, employ advanced analytical techniques, and
perform quality control across runs and reagent/bead
lots. This was labor-intensive, introduced additional op-
portunities for error, and multiplied versions of data and
analyses. Second, existing Luminex tools did not enable
smooth handoff of quality-controlled data from labs to
central network statisticians and principal investigators,
nor provide transparency into data excluded from ana-
lysis by the labs as part of quality control.
The inherent complexity of multiplexed immunoassays
makes robust, transparent quality control techniques
particularly vital to achieving reproducibility, reliability
and comparability of such assays [8,15-18,32-35]. Cus-
tom immunoassays that use Luminex technology, such
as BAMA, can be highly reproducible; for example,
BAMA has been validated for use in analyzing HIV-1
specific antibody responses in clinical trials [4,36], data
in preparation for publication by Georgia Tomaras].
Nevertheless, variability in assay execution, analysis, and
results is currently considered a key inhibitor of the reli-
able use of commercially available multiplexed assays in
clinical applications, such as diagnostic biomarkers or
surrogate endpoints for clinical trials [15,17,18,35,37-39].
One recent study of variability in multiplexed cytokine
assay results showed significant variation across every
participating lab and/or material lot for every reagent kitand multiplex platform employed (including several
Luminex systems) [17]. Large-scale efforts to develop
assay “harmonization” guidelines [37-42] emphasize the
importance of facilitating and sharing quality techniques
that can be used to overcome intra- and inter-assay vari-
ability and stabilize assay performance across labs.
Growing efforts to develop reporting standards for im-
munoassay protocols and results [42-46] further
emphasize the importance of clearly tracking and
reporting variables (particularly quality control proce-
dures) that affect assay consistency.
In response to the limitations of existing software tools,
the HIV Vaccine Trials Network (HVTN) and the Statis-
tical Center for HIV/AIDS Research & Prevention
(SCHARP) at the Fred Hutchinson Cancer Research Cen-
ter collaborated with LabKey Software to enhance the
freely available, open source LabKey Server system [47,48]
to support management, analysis and quality control of
Luminex immunoassay data. Data may be produced by ei-
ther customized or commercially available (kit-based) as-
says. The software may be particularly helpful to research
organizations who seek greater control over analysis and
quality control techniques; to consolidate, simplify and
standardize calculation and monitoring procedures; and
(as shown in Figure 1) to facilitate secure collaboration.
Steps for a Luminex immunoassay
To provide context and terminology for software discus-
sions, we briefly sketch an abbreviated set of experimen-
tal, analysis and quality control steps that might be used
as part of an immunoassay based on Luminex xMAP
technology. Note that experimental steps, materials and
terminology vary with the type of immunoassay; simi-
larly, analysis and quality control techniques continue to
be active areas of research [15,16,27-30,32,34].
Figure 2 shows how you might evaluate the binding of
plasma antibodies from study participants (e.g., immuno-
globulin A (IgA) antibodies) to a panel of analytes (e.g.,
virus envelope (ENV) proteins (antigens)). Experimental
steps:
(1) Conjugate each analyte with a different type of bead.
Each bead type contains a mixture of red and
infrared dyes whose ratio can produce a spectral
signature that uniquely identifies the bead type
(and thus the analyte).
(2) Mix bead/analyte complexes with a sample in each
plate well. Sufficient numbers of each type of bead
must be deposited in each well to satisfy thresholds
for statistically significant results. Optionally,
unbound (“blank”) beads may be included in the
bead mixture to allow subtraction of fluorescence
from non-specific binding to beads. The type of
















Figure 1 LabKey server data flows. This figure shows how Luminex data, quality control (QC) information, analyses and visualizations might
flow between collaborating clinicians, lab technicians, statisticians, study project managers, and scientists. In this way, LabKey Server can facilitate
the smooth, secure flow of information between collaborating teams during large-scale immunological studies, such as HVTN’s recent immune
correlates work. Upon publication of study results, the anonymized data, analyses and visualizations produced by such a scientific team can be
shared publicly by simply changing permission settings.
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whose concentration is known and used to calculate
a reference curve (ii) A titrated quality control,
whose concentration is known and used to calculate
a reference curve (iii) An unknown, such as serum
from a study participant (iv) A positive or negative
control (v) A background well, which contains only
buffer and is used for subtracting that results from
non-specific binding of the detector. Samples are
usually replicated in several wells.
(3) Incubate, then rinse. This removes excess sample.
(4) Add detector conjugated to R-phycoerythrin. The
detector and its attached fluorochrome later serve as
reporter for the binding of sample material to the
bead/analyte complex. The detector is sometimes
called the conjugate for the experiment.
(5) Incubate, then rinse. This removes excess detector.(6) Use two lasers to measure bead number and
sample binding. Typically, flow cytometry and two
lasers are used to make single-bead measurements.
For each bead, one laser excites the bead’s dye,
allowing identification of the bead type (and thus the
analyte) from the red/infrared ratio of light, as well
as detection of beads of incorrect size (such as
doublets or fractured beads). A second laser excites
the detector-bound fluorochrome, allowing
measurement of sample binding. For each type of
analyte in each well, the instrument reports the
median fluorescence intensity (FI) for the bound
detector for all beads coupled with that analyte.
On a per-run basis, analysis and quality control of
results may include: normalization to account for back-
ground fluorescence, exclusion of suspect data, calculation
Figure 2 Luminex immunoassay. This figure sketches an experimental process that might be used in a Luminex immunoassay used to evaluate
the binding of a panel of HIV envelop proteins to plasma IgA antibodies. The figure does not include analysis or quality control steps.
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these curves to interpolate estimated concentrations of
unknowns, and other steps. Performing quality control
across many assay runs may involve: calculating represen-
tative metrics for each standard curve for each run, plot-
ting these metrics and expected ranges on Levey-Jennings
[49] charts to determine outliers, excluding data from ana-




LabKey Server is a web application implemented in Java.
It runs on the Apache Tomcat web server and stores its
data in a relational database, either PostgreSQL orMicrosoft SQL Server. LabKey Server has been tested on
computers running Microsoft Windows and most Unix
variants, including Linux, Macintosh OSX and Solaris.
LabKey Server’s tool for Luminex is packaged in a
Java-based module that encapsulates user interface ele-
ments and calculation logic for designing, processing
and displaying structured assays of various kinds. The
tool can leverage a customizable transform script that
performs Luminex-specific analysis calculations during
import of assay data. If included, this script is also re-
run automatically when data from a titration are ex-
cluded from analysis because the exclusion affects the
analysis results. The default Luminex transform script is
written in R, but many other programming languages
could be used (e.g., Perl, Python, or Java).
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ule are covered elsewhere [47]. LabKey Server v12.3,
available in December 2012, is the 25th official, public re-
lease of the platform since 2005.
Configuration of scripting
To access all features of the LabKey Server tool for
Luminex, the R scripting environment must be installed
and configured on the server. To leverage the default
Luminex transform script (labkey_luminex_transform_
script.R), one must also install the script, its utility script
(youtil.R), the Ruminex R package [27], and required R
packages (Rlabkey, xtable, drc and Cairo). See Additional
file 1 to obtain the first three; the other R packages are
available from the Comprehensive R Archive Network
(CRAN) [50].Results
Overview of the Lumimex tool
When a researcher imports Luminex run data into a
LabKey Server, the researcher is prompted to enter rele-
vant metadata about the batch of runs, the run itself, in-
cluded analytes and relevant titrations. Metadata include
information required for calculations (e.g., normalization
options, and desired standard for each analyte) and ex-
perimental characteristics that can be used for tracking
purposes (e.g., experiment performer and reagent lot
number). The system can be configured to use an R
script to automatically analyze raw data and metadata to
determine dose–response curves for titrations, estimate
concentrations using these curves, identify outliers, de-
termine quality control metrics for curves and plot
curves. Unreliable experimental data can be flagged for
exclusion from analyses. When a transform script is
configured, the system automatically provides Levey-
Jennings quality-control charts and allows users to de-
fine expected ranges using baseline sets of runs. Assay
results can be integrated with other data types, such as
specimen information and clinical data for study partici-
pants. The Luminex tool displays all source data, quality
control exclusions, calculated values and curves in a se-
cure, interactive, web-based interface.
Options for leveraging the tool
LabKey Server’s tool for Luminex can be accessed in two
ways:
 By installing and configuring a LabKey Server
instance. This option allows you to administer and
customize a private LabKey Server for your lab or
organization. The “Availability and Requirements”
section of this paper explains how to obtain
installers and/or source code. By logging into to the Atlas Science Portal [51]. This
option is available to qualified researchers at many
of the consortia participating in the Global HIV
Enterprise [47,52,53]. To inquire about access,
contact atlas@scharp.org.Documentation, tutorials, live demo, and context-
sensitive help
Full documentation and tutorials for setting up, config-
uring and using LabKey Server and its Luminex assay
tool are available at http://www.labkey.org. This docu-
mentation is updated regularly to match the currently
released version of LabKey Server. The basic and
advanced Luminex tutorials [54,55] provide detailed
walk-throughs of Luminex setup and scenarios. They
also include a troubleshooting guide [56] that helps
users interpret and fix error messages from Luminex
transform scripts, plus address problems with script-
calculated values, such as curve fits. The tutorials are ac-
companied by live demos [57] that allow visitors to
interact with Luminex features that do not require
editor-level permissions. For each page in the Luminex
workflow, the software provides a context-sensitive Help
link in the upper right corner that leads to a relevant tu-
torial or documentation page.Assay file formats
LabKey Server understands Microsoft Excel® files output
by Bio-Plex Manager™ [58] for each Luminex assay plate
run. Bio-Plex Manager is software that runs several types
of Luminex devices. The LabKey Server tool for
Luminex has been tested with the results of 96-well
plate assays. It is expected to be compatible with newer,
larger plates, such as those with 384 wells.
Each run file includes a separate worksheet for each
type of bead (and thus each analyte). Each sheet displays
a header with run metadata, one or two data tables, and
a footer with calculated parameters and flags. Data tables
report results provided by the instrument, either on a
per-well basis (raw data) or on a per-sample basis (sum-
mary data). If summary data are reported, each row sup-
plies an average for all sample replicates. Some files
contain both raw and summary data tables.
Each row in a data table reports the sample type (back-
ground, standard, control or unknown), sample identifier,
well location (for summary data, multiple are shown), sam-
ple description (often an identifier that can map the sample
to its source specimen and study participant), FI (fluores-
cence intensity averaged across replicates for summary
data), FI minus mean background well FI, coefficient of
variance, expected concentration (for titrations only), dilu-
tion, bead count (for raw data only), and other columns.
Figure 3 Assay design editor. An assay design describes the data fields imported from a run data file, the metadata collected from the user
during import, and other properties of the assay, such as the location of the transform script run during data import. For each field, the design
can define an expected range; default value; acceptable values; conditional formatting; display formatting; editability; and a range of other
settings [47]. Custom, lab-specific fields can be defined at the batch, run, and analyte levels. If the transform script is customized to output new
fields (such as calculated values) and these fields need to be stored in the database, corresponding destination fields must be added to the assay
design.
This screenshot shows a portion of an assay design and illustrates how customization of such a design can facilitate collection of run-specific
data from the user during data import. Here, the Isotype run metadata field (highlighted in gray) has been defined as a lookup to a pre-defined
list (a simple table). This list, also called Isotype, populates a drop-down list of data entry options that are presented to the user during run
import (as shown in Figure 4). The Isotype field has been further customized to default initially to IgA (one of the options defined by the lookup
list), then after that to the Last entered value.
Eckels et al. BMC Bioinformatics 2013, 14:145 Page 6 of 17
http://www.biomedcentral.com/1471-2105/14/145Usage scenario for the tool
To analyze and perform quality control on Luminex
data, a lab might follow these steps:
1. Set up an assay project. After setting up a LabKey
Server, an administrator creates an assay-type
project on the server with appropriate permissions
for user access. It provides a central location for
managing descriptions of Luminex assays and
associated run data.
2. Create an assay design. An assay design [47] both
describes the content expected for a particular typeof assay run file and provides a framework for
importing many runs and their associated metadata
in a standardized manner. An administrator can
either select the default Luminex assay design, or
import a Luminex assay design archive that is
tailored to support the default transform script. Both
designs can be further customized, as shown in
Figure 3. When usage of a transform script is
desired, the path to this script is entered in the assay
design.
3. Import data and enter metadata. After an
administrator has created an assay design in the
Figure 4 Run properties data entry form. This image shows an example of a data entry page for run metadata provided to the user as part of
the run import process. It illustrates how pre-set defaults and lookups defined in an assay design (such as the one shown in Figure 3) can ease
and standardize data entry during run import. Here, the Isotype field shows a default of IgA and provides a drop-down list of other options. Both
the default and list of options were configured in the assay design shown in Figure 4. The use of a standardized vocabulary for data entry makes
it easier and more accurate to aggregate, filter and report on the information entered. The use of default values can speed data entry when the
same values apply to many runs.
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server. As part of this process, the assay design
guides the collection of appropriate metadata for
the assay run, as shown in Figure 4. Certain
metadata are used to control Luminex-specific
data processing. For example, information
collected may determine processing steps for
inputs to calculations (such as normalizations for
background fluorescence), identify the standard(s)
used for calculating interpolated concentrations,
or associate analytes with metadata (such as bead
lots). Other metadata are used to annotate the
run, run analytes, and/or batch of runs. During
import, the transform script automatically
performs calculations on the data and the system
flags certain data for quality control (as discussed
below in the “Calculations” section). Several files
may be imported together as part of one run,
allowing standards in one file to be associated
with results in another.
4. Explore results. Curve fits and related results are
calculated automatically by the transform script for
each run during the import process. Results include
curve fit parameters, estimated concentrations
interpolated from calculated curve fits for standardtitrations, and metrics calculated from curve fits,
including EC50 (effective concentration at 50% of
the difference between the asymptotes of a dose–
response curve), AUC (trapezoidal area under the
curve) and HighMFI (highest mean FI). Calculated
results and data from run files are displayed together
in grid views. The system provides curve
visualizations based on both 4- and 5-parameter
logistic regressions (4pl and 5pl), as shown in
Figure 5. Users can explore their data through
sorting, filtering and customizing grid views; using
built-in visualization and analysis tools; or building
custom SQL queries or visualizations [47]. For
example, LabKey Server’s built-in R scripting
environment allows statisticians to define R scripts
that produce visualizations and associate them with
certain kinds of results.
5. Perform within-run quality control. Questionable
results can be excluded from analysis on a per-
analyte or per-replicate-group basis. If a replicate
group of wells for a titration is excluded, the
transform script is re-run to recalculate curves
and associated results. Figure 6 shows how the
system applies red highlighting to all excluded
data.
Figure 5 Standard titration curve visualization. The system
provides a PDF file that contains a plot for each curve fit calculated
by the transform script for each standard or quality control titration.
The plot also displays the source data used to calculate the curve.
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automatically plots Levey-Jennings charts for four
metrics of performance (4pl EC50, 5pl EC50, AUC
and HighMFI) for both standards and quality
controls chosen for each analyte. Users can select a
suite of baseline runs (a “guide set”) to establish
expected ranges for analyte-specific standard metrics
for all runs associated with the same lot of
experimental materials, as shown in Figure 7. These
ranges (+/− one, two and three standard deviations)
are displayed on the Levey-Jennings plot for each
metric for the analyte standard, as shown in
Figure 8. For each run associated with the same lot
of materials, quality control metrics that fall outside
of expected ranges are flagged for review, as shown
in Figure 9. Standard curves for selected runs can be
displayed together to help identify inconsistencies in
curves across runs, as shown in Figure 10.
7. Share quality-controlled data with collaborators.
After a lab has completed quality control for a set of
runs, a lab data manager copies finalized data into a
shared, study-type project. A study-type project
serves as an integration and analysis hub for many
types of related data for a study (e.g., specimen
information, study participant demographics and
results from other assays) [47,59]. Collaborators
with appropriate permissions can use the server’s
web portal to view and analyze this data.
Administrators can set up custom views or SQL
queries that allow different parties (such as labtechnicians, statisticians and project managers) to
see the data in their own preferred formats. Role-
based, inheritable and customizable permission
settings [47] support controlled, secure sharing
within a lab, between labs, between organizations,
and/or with the general public. Collaborating
scientists can use the shared data portal to bring
different perspectives to results, explore alternative
analysis approaches, and collaborate efficiently on
publication.
8. Publicly share data and analyses as part of a
publication. Upon publication of results in a
scientific journal, specified subsets of anonymized,
releasable data can be publicly shared on a LabKey
Server web portal alongside contextual information
and tools, including quality control information and
analytical scripts. Providing public, interactive
access to publication-related data allows a wider
pool of scientists to explore the results and
investigate alternative analytical approaches.
Interactive release of data, quality control
information, and analytical tools also supports
study reproducibility [35].Calculations
Calculations performed on Luminex data fall into three
categories: automatic calculations performed by the ser-
ver, automatic calculations performed by the transform
script, and optional calculations performed by the script.
Calculations by the script only occur if the script is asso-
ciated with the assay design. Calculations by the system
and the script are performed during data import.
Additionally, if data for a replicate group of wells in a
titration are excluded, the transform script and its calcu-
lations are re-run.
Automatic calculations and flagging performed by
the server. LabKey Server provides automatic calcula-
tion of coefficients of variation (CVs) and provides flag-
ging for outliers of various kinds to facilitate human
review.
For quality control of multiplexed immunoassays, re-
searchers typically pre-select acceptable thresholds of vari-
ation across replicates and use these thresholds to flag,
review, and exclude dubious data in a standardized fashion.
CVs are used to measure variability for different kinds of
replicates (samples, assay runs, material lots, analysis labs,
etc.) and identify questionable outliers or patterns that may
be artifacts of experimental conditions [15,17,33,34,60].
Outliers can bias top asymptotes, bottom asymptotes, and
slope parameters [60,61]. CVs for both intra- and inter-
assay measures may also be monitored over time to iden-
tify changes in experimental conditions that may affect the
accuracy and comparability of results [15].
Figure 6 Highlighting for excluded wells. When a user excludes data from analysis (either on a per-replicate-group or per-analyte basis), the
excluded rows of data are flagged with red highlighting in the user interface, as shown here.
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data, LabKey Server calculates the CV of the FIs of each
replicate group (sample/dilution/antigen combination).
CVs are stored with each well-level row and measure
variability across replicates. They are displayed as per-
cents (%CVs).Figure 7 Creation of a guide set. This figure shows how baseline runs ar
for analyte standards and quality controls for runs that share a common loLabKey Server adds a quality control flag to each data
row whose reported FI is greater than 100 and whose %
CV is greater than 15 (for unknowns) or 20 (for standards
and quality controls). FI > 100 is used as a threshold to
save review time; for our collaborators, only samples that
are potentially “positive” (significantly changed withe incorporated into a “guide set” used to define expected value ranges
t of reagents (e.g., beads).
Figure 8 Levey-Jennings chart for cross-run quality control. Levey-Jennings charts can help visualize changes in a quality control metric over
time, across runs, and across material lots. This Levey-Jennings chart shows expected ranges for EC50s for standards run for the ENV2 analyte. The
transform script calculated these EC50s using the Ruminex package and 5pl curve fits, so they are displayed on the EC50 – 5pl Rumi tab of this
interface.This example shows differences in expected EC50 ranges for two groups of runs, each of which is associated with a different lot of
experimental materials.
The example also shows a trend over time in EC50, which might suggest decay in experimental conditions or materials. Such decay would
require further investigation. It might require exclusion of results from certain days or material lots, replacement of old reagents, investigation of
material supply consistency, or other such measures. Early identification of such a trend can allow a lab to take corrective measures before a
quality metric falls outside of acceptable bounds and assay runs must be rejected. Outliers visible in this plot are flagged for review, as shown in
Figure 9. Charts can be exported to PDF using the PDF icon.
Figure 9 Active and inactivated quality control flags. Metrics used for cross-run quality control (4pl and 5pl EC50s, AUC and HighMFI for
standard or quality control titrations) are flagged for review when they fall outside the maximum expected range. As visualized in Figure 8, the
maximum expected range around the mean for a metric is +/−3 times the standard of deviation of the relevant “guide set” (benchmark group of
runs). Flagged metrics are highlighted in red, plus listed in a separate column, which facilitates review. Users can inactivate quality control flags
for metrics that have been reviewed and deemed acceptable. Once a metric for a run has been inactivated, its red highlighting is removed and
its listing is crossed out, as shown here for the 5pl EC50 for the run at the top of the list.
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Figure 10 Multi-curve plots of standard titrations for several runs. Plotting standard curves for several runs together (a.k.a., creating a curve
“graveyard” [15]) helps visualize any inconsistencies in data and curve fits between runs. The curves shown here are 4pl standard titration curves
for the same data used in Figures 7, 8 and 9. Users can select which curves to plot together. Plots are provided for both FI and log(FI), but only FI
is shown here.
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umns flagged through this process are highlighted in red.
LabKey Server can automatically provide additional
flagging and reporting of outliers. Assay design fields
can be configured with arbitrary conditional formatting
settings that automatically color code values when
viewed in the user interface or in Excel file exports. A
user can set up saved, custom views that automatically
filter results to show only data rows that exceed user-set
thresholds for user-selected measurements. Further-
more, as mentioned above, the system’s analyte- and
replicate-specific exclusion options can be used to sys-
tematically add custom flags and exclusions, which the
server displays in summary reports.
Automatic calculations performed by the default
transform script. The script automatically applies a
conversion function to normalized FIs to account for
negative values potentially introduced by the removal of
blank bead and/or background fluorescence. Currently,
the script calculates: converted FI = max(FI, 0) + 1.
When calculating 5pl curve fits, the default transform
script uses the Ruminex R package [27], which in turn
uses the drc R package [62]. When calculating 4pl curve
fits, the script uses the drc R package directly. Users can
edit the transform script to use alternative strategies for
performing 5pl and 4pl curve fits [27,63,64], including
using custom seed and optimization functions. Users
can also add new calculations to the transform script.Optional calculations performed by the default
transform script. The default transform script enables
users to opt to:
 Normalize FI by subtracting blank bead and/or
background well FI before calculating curves or
interpolating unknowns. This subtracts fluorescence
signal that is due to non-specific binding to the
beads.
 Log transform normalized FIs before calculation of
curve fits, which can help stabilize variance
extremes [27].
 Apply weights to the squared errors used in
goodness of fit optimization calculations. Weighting
can help account for lower variance at lower FI
(heteroscedasticity). This improves curve fits,
particularly at the low range, thus expanding the
useful range of data. Using the transform script,
these weights can be arbitrary (e.g., weight = 1/FI1.8)
 Calculate "positivity" by determining whether the
value for each analyte has increased relative to a
baseline value and also exceeds an analyte-specific
threshold. This is helpful, for example, when you
wish to determine whether measurements for an
individual in a trial have increased relative to
baseline, pre-trial values. Both the baseline and
threshold for each analyte are entered during run
import.
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Additional features of LabKey Server are likely to be par-
ticularly helpful to users of the Luminex tool. These in-
clude: a fine-grained security model; auditing; options for
exporting data in a variety of formats; file upload and shar-
ing; and client APIs (application programming interfaces)
for building custom interfaces and workflows using a var-
iety of common languages (e.g., JavaScript, Java, Python,
R, etc.) [47,48,59].
LabKey Server also allows researchers to integrate assay
results (such as Luminex results) with related study data
[47,59]. Specimen identifiers in run data files can be
mapped automatically to study-specific specimen identifiers
(or participant/visit identifiers). This allows linkage and in-
tegration of specimen, experimental and clinical data.
The system also supports assays and techniques com-
monly used by immunologists, including ELISAs, neutraliz-
ing antibody assays [59], flow cytometry [65,66], proteomics
[48,67], and next-generation sequencing [68,69]. Further-
more, LabKey Server also supports the description, man-
agement and analysis of novel assay types [47].
Current usage
The full set of features described here only became avail-
able in April 2012 with the release of LabKey Server
12.1, so adoption of the improved Luminex assay tool
has been promising. As of January 2013, the AtlasTable 1 Comparison of software tools
Features Luminex
xPONENT
Graphical user interface +
Runs a Luminex-type instrument +
Built-in, automatic quality control flagging of some kind +
Built-in, automatic curve fits for titrated controls and
unknowns, not just standards
+
Built-in mechanism for choosing a standard from a different
plate
+
Option of weighting squared errors by to 1/FI2 +
Can subtract blank bead fluorescence -
Can generate Levey-Jennings plots for cross-run quality
control
-
Support for scripting in some language -
Client APIs for development of custom interfaces -
Can weight squared errors with custom functions -
Fully customizable 5pl algorithm -
Open source -
Freely available without time restrictions -
Portal for secure data sharing -
This table compares LabKey Server with a representative sample of software used f
aims to show how LabKey Server provides advantages over other existing software
Documentation for many tools was incomplete, so the table provides only a reasonScience Portal maintained by SCHARP, HVTN and their
collaborators contained a total of 1,081 Luminex runs
contributed by at least three separate labs.
Discussion
Overview
Among software for Luminex analysis and quality control,
LabKey Server stands out most distinctively in its support
for customization, traceable quality control, and secure data
sharing. These capabilities can help labs develop and adopt
the new methods; simplify and standardize workflows; and
securely, smoothly share information with collaborators.
LabKey Server is also notably unique among Luminex-
specific tools for being both open source and freely avail-
able (Apache 2.0 license [70]). Current, notable limitations
include a lack of support for running Luminex instruments
and a requirement that input run files conform to the Excel
file format output by Bio-Plex instrument software.
Alternatives
Beyond LabKey Server, only a few software tools provide
Luminex-specific support, and all of those tools provide
only limited customizability. A much wider range of
software tools provide significant customizability along-
side general-purpose statistical features, but those tools
do not inherently support Luminex-specific workflows.









+ + + + - +
- + - - - -
+ + - - - +
+ - - - - +
+ + - - - +
+ + + + + +
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or analysis and quality control of research Luminex immunoassays. This list
tools, not to compare all capabilities relevant to Luminex analysis.
able inference of feature availability.
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Luminex (Luminex xPonent™ [71], Bio-Plex Manager
[58], and MiraiBio MasterPlex QT™ [72]) and three
general-purpose statistical tools (GraphPad/Prism® [73],
Microsoft Excel [74], and R [75]). To highlight tradeoffs,
features are roughly ordered from greatest Luminex spe-
cificity to greatest scope for customization.
This table does not aim to address tools for scientific
data sharing [47]. Furthermore, the table only includes
Luminex-specific software designed for research assays,
not software designed to support standardized diagnostic
tests. Research assays typically require greater scope for
cutting-edge analysis than manufacturer-defined diag-
nostic tests.
Advantages
LabKey Server’s tool for management and analysis of
Luminex immunoassay results can help labs and re-
search organizations to:
(i) Efficiently perform complex analyses of
high-content data. The nature of multiplexed
immunoassays results in a significant amount of
information per experimental run. The tool can
help teams efficiently manage and quickly analyze
the complex, multidimensional data produced by
such assays.
(ii) Facilitate networked research through smooth,
secure sharing of Luminex results. A central,
shared data portal/repository can prove particularly
useful to research networks and consortia who
employ central data management and statistics
groups to execute study-wide and/or cross-study
analyses based on data pooled from collaborating
labs [47,51,76]. As shown in Figure 1, labs can use
such a portal to supply statisticians with data and
quality control information in a secure fashion.
Central data managers can use the system’s
reporting tools to efficiently monitor and
troubleshoot study progress. Principal investigators
(and others with appropriate permissions) can gain
transparency into study progress, analyses and data,
as well as explore alternative analysis approaches
and collaborate on publications. Using a central
repository can also help prevent loss of valuable
data from individual computers. After study
publication, a subset of releasable, anonymized
study results can be made publicly available on the
organization’s data portal by changing permission
settings.
(iii) Retain raw Luminex data, quality controlled
data, and analyses to make them available for
later re-analysis. LabKey Server stores raw run
data from the instrument, quality controlinformation, calculated values, final datasets,
visualizations, and the original run data files. Data
records that have been flagged for quality control
can be excluded from analysis without deletion.
When data is stored in a shared repository,
statisticians, labs and principal investigators can
examine or export copies of the data as it looked
at different stages of processing (e.g., with and
without quality control exclusions).
(iv) Consolidate, simplify and standardize lab
workflows by using one primary software tool
for Luminex analyses. Eliminating the
labor-intensive steps necessary to move data
between tools for different calculations can
increase efficiency, foster standardization and
reduce opportunities for error. If the software is
deployed on a shared portal, users have access to
the same version of the tool and the same analysis
algorithms without the need to install updates on a
multiplicity of machines [59].
(v) Customize calculations and visualizations. Labs
can adopt new analysis and quality control
techniques without adopting additional software
tools or complicating workflows. They can use
scripting and custom assay designs to incorporate
the latest algorithms (e.g., new techniques for
curve fitting), visualizations (e.g., custom R plots)
and processing steps (e.g., subtraction of blank
bead fluorescence) while still providing users with
a friendly, graphical user interface. Labs can test
out new analytical techniques and transform
scripts without disrupting mainline workflows by
establishing separate assay designs for exploratory
analytics.
(vi) Track quality control across runs and reagent/
bead lots using Levey-Jennings plots and outlier
flagging. Both LabKey Server and existing
Luminex-specific software packages enable both
automatic and manual identification of outliers
within runs. However, only LabKey Server provides
extensive support for quality control tracking across
runs and material lots using Levey-Jennings plots.
(vii) Gain flexibility in plate layouts and titration
analyses. LabKey Server allows a user to associate
multiple standards with each analyte, automatically
perform curve fitting for all titrations (including
quality controls and unknowns, not just standards),
and select a standard on a different plate for use in
interpolation of concentrations of unknowns.
Bio-Plex Manager does not currently allow any of
these options without rerunning analyses. Other
software supports only some of these options.
(viii) Leverage LabKey Server platform features. The
base system provides extensive support for data
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workflow interface development. It also supports
other assays and techniques commonly used by
immunologists.
(ix) Use open-source, freely available tools. At
present, LabKey Server is the only open source tool
with a graphical user interface that provides
substantial support for Luminex-specific scenarios.
The R scripting environment is also open source, as
are a wide variety of R statistical analysis packages.
Using open source tools can provide advantages in
transparency, cost and extensibility.
(x) Facilitate assay harmonization across
organizations. Overcoming variability and
reproducibility issues for commercially
available, multiplexed immunoassays for
cytokine measurement is considered key to
broadening the viable applications of such
assays [37,38]. To harmonize assay results,
researchers identify experimental and analytical
variables that strongly influence assay
performance and use them to develop quality
control guidelines that improve assay
reproducibility across labs, material lots,
organizations, etc. Identification of such
performance variables requires sharing not just
final results, but also protocol records, quality
control information, data processing
methodologies, and (possibly) analytical tools
across collaborating organizations. To our
knowledge, LabKey Server has not yet been
employed for assay harmonization at a scale worthy
of note; nevertheless, the system seems particularly
well-suited given its support for sharing just this
kind of information and tools. An installation of
LabKey Server (the Atlas Science Portal [51]) has
already been used for wide-scale proficiency testing
(comparison of the performance of a standardized
protocol across many labs) of a neutralizing
antibody assay [59].
Limitations
Current limitations on the use of LabKey Server for ana-
lysis of Luminex experiments include:
(i) No support for running a Luminex instrument or
designing Luminex plate layouts. Software such
as Luminex xPonent, Bio-Plex Manager or
MILLIPLEX Analyst™ [22] is currently required for
running instruments that leverage Luminex xMAP
technology.
(ii) Limited Luminex data file format compatibility.
Currently, the LabKey Server tool for Luminex
only understands data files in the Excel formatoutput by the Bio-Plex Manager software. However,
the system can still infer the structure (column
names and data types) of other tables of data,
which allows users to quickly import other kinds of
tabular data files, such as metadata files. Custom
SQL queries can join imported tables of metadata
to other kinds of Luminex data for display as
custom data grids [47].
(iii) Familiarity with R recommended for extensive
customization of analyses. Customization of
certain aspects of data processing and analysis (e.g.,
selection of background FI subtraction settings)
can be made through the user interface. However,
making extensive changes to the default transform
script (e.g., substituting a new curve fit algorithm)
requires some knowledge of the R programming
language. At the same time, transform scripts can
be written in most programming languages (e.g.,
Perl, Python and Java), not just R.
(iv) Certain interfaces reflect terminology specific to
certain kinds of immunoassays. The Levey-Jennings
charting interface uses terminology consistent
with the kind of immunoassays shown in Figure 2.
For such experiments, analytes are antigens and
the antibodies being measured are
immunoglobulin isotypes. The interface can still be
useful for other types of experiments as long as
this terminology is understood.
Future enhancements
LabKey Server undergoes ongoing development, culmin-
ating in 3–4 releases per year, so features and user inter-
face refinements are regularly added to the platform.
Features that may interest Luminex users have already
been added during the period this paper has been under
review. These improvements are available in LabKey
Server v12.3 (released December 2012) and include:
multi-curve titration plots for overlaying and comparing
results from several runs (shown in Figure 10), the
ability to run arbitrary numbers of transform scripts
sequentially during data import, enhanced heuristics for
identifying filter options for columns in data grids,
and tools for anonymizing data for public release.
One ongoing focus of development is support for
ancillary studies [77], particularly “freezer studies” that
leverage valuable, stored specimens to gain novel
insights through new experiments, such as Luminex
immunoassays.
Conclusions
LabKey Server’s support for Luminex data analysis and
quality control allows labs to consolidate, customize and
standardize data analysis workflows, which can elimin-
ate labor-intensive and error-prone steps. Using
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able teams to securely share data, analyses, quality
control information, and related documents. These
capabilities can be particularly helpful to research or-
ganizations whose success depends on smooth collab-
oration between labs, central data managers, statistical
teams and principal investigators. The open source li-
cense [70] for LabKey Server and its Luminex tool
allow other researchers to freely leverage, customize
and improve this software.Availability and requirements
LabKey Server source code and compiled binaries
The LabKey Server open source software is freely
available for download at http://www.labkey.org
under the terms of the Apache License 2.0 [70].
This site also provides documentation, tutorials and
demos for users and developers, along with instruc-
tions for developers who wish to contribute code to
the project through the LabKey Server Subversion
repository.
Compiled binaries for Windows, Unix, Linux or
Macintosh installation are available for free through
LabKey Software at http://www.labkey.com. A graphical
installer is available for computers running Windows XP
or later. It includes the LabKey Server web application;
the Apache Tomcat web server, v6.0.35; the Sun Java
Runtime Environment, v1.7.0-29; the PostgreSQL data-
base server, v9.2.1; and additional third-party compo-
nents. Note that the installer does not include R. To
access all features of the LabKey Server tool for
Luminex, the R scripting environment must be installed
and configured on the server.
 Project name: LabKey Server
 Project home page: http://www.labkey.org
 Operating system(s): Platform independent
 Programming languages: Java, JavaScript, R, Perl,
Python, SAS, etc.
 Other requirements, as of LabKey Server v12.3:
Apache Tomcat 6.x; Sun Java Runtime
Environment 6 or 7; and either PostgreSQL
(8.3, 8.4, 9.0, 9.1, or 9.2) or Microsoft SQL Server
(2008 R2 or 2012 with Service Pack 1). Check the
project site for latest requirements of the most
recent release.
 License: Apache License 2.0 [70].Access to the Atlas Science Portal
Access to Atlas [51] is available to qualified researchers
at many of the consortia participating in the Global HIV
Enterprise [47,52,53]. To inquire about access, contact
atlas@scharp.org.Additional file
Additional file 1: Zip archive containing the transform script,
Ruminex package, assay design archive, and supporting files. This
.zip archive can be unzipped to obtain the following files:
• LabKey transform script for Luminex: labkey_luminex_transform_script.R.
• Utility script used by the transform script: youtil.R.
• Ruminex R package, v0.0.9: Ruminex_0.0.9.zip.
• Luminex assay design archive tailored for the transform script: Luminex
Assay 200.xar.
• LabKey Server list archive useful for populating fields in the assay
design: Luminex_ListArchive.lists.zip.
These files have been tested against LabKey Server v12.3, released in
December 2012. For future releases of LabKey Server, we recommend
obtaining updated versions of these files. The most current versions are
provided as part of the advanced tutorial for Luminex [55]. LabKey Server
tutorials and documentation available at http://www.labkey.org are
updated regularly to match the currently released version of LabKey
Server.
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